Methods of diagnosing bladder cancer

• US 6,998,232 B1
• Filed: 04/04/2001
• Issued: 02/14/2006
• Est. Priority Date: 09/27/1999
• Status: Expired due to Fees

• Current Assignee: Quark Pharmaceuticals, Inc
• Original Assignee: Quark Biotech, Inc.
• Inventors: Feinstein, Elena, Mor, Orna
• Primary Examiner(s): Johannsen, Diana B.
• Application Number:
  US09/825,682
• Time in Patent Office: 1,777 Days
• Field of Search: 435/6, 435/7.1, 435/91.2, 435/91.51, 536/23.5, 536/24.31, 530/350
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G16B 25/00 ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
• CPC Class Codes: G16B 25/10 Gene or protein expression profiling; Expression-ratio estimation or normalisation

Abstract

There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of a least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering to a patient a therapeutically effective amount of chemical compound are also provided.

Claims

1. A method of diagnosing bladder cancer in a human subject which comprises the step of:

determining, in a sample from the human subject, the level of expression of at least two polynucleotides, wherein a higher level of expression of the polynucleotides compared to the level of expression of the polynucleotides in a human subject free of bladder cancer is indicative of bladder cancer, and wherein the polynucleotides are selected from the group consisting of polynucleotides having SEQ ID NOS;

57, 56, and 41.

2. The method according to claim 1, wherein the determining step includes using mRNA from an expressed gene to hybridize to at least two polynucleotides selected from the group consisting of the polynucleotides having SEQ ID NOS:

57, 56, and 41.

3. The method according to claim 1, wherein the determining step includes a step of using RT-PCR technology.

4. The method according to claim 1, wherein the determining step comprises using a specific antibody to detect the presence of a polypeptide encoded by one of said polynucleotides.

5. The method according to claim 1, wherein the bladder cancer is transitional cell carcinoma.

6. The method of claim 1 wherein the level of expression of at least three polynucleotides is determined.

7. The method of claim 1 wherein the polynucleotide having SEQ ID NO:

57 is a Homo sapiens syndecan-1 polynucleotide wherein the polynucleotide having SEQ ID NO;

56 is a Homo sapiens hepatocyte growth factor activator inhibitor type 2 polynucleotide.